Guardant Health, Inc. (GH) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $114.00: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 10%; Elevated put/call ratio: 1.91; Below-average business quality.
Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests (Guardant360, Shield, Guardant Infinity) for cancer detection, therapy selection, and monitoring. It earns revenue primarily from clinical test volumes reimbursed by Medicare and... Read more
Sell if holding. Engine safety override at $114.00: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 10%; Elevated put/call ratio: 1.91; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Guardant Health, Inc.
Latest news
- Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test — benzinga May 20, 2026 positive
- Guardant Health Announces FDA Approval Of The Company's Liquid CDx To Advance Blood-Based Comprehensive Genomic Testing — benzinga May 20, 2026 positive
- JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $135 — benzinga May 8, 2026 positive
- Barclays Maintains Overweight on Guardant Health, Raises Price Target to $120 — benzinga May 8, 2026 positive
- Evercore ISI Group Maintains In-Line on Guardant Health, Raises Price Target to $95 — benzinga May 8, 2026 positive
Generated 2026-05-20T23:21:20Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -40.1%. Quality floor flags this regardless of sector context.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $114.00: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 10%; Elevated put/call ratio: 1.91; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $106.92. Score 5.7/10, moderate confidence.
Take-profit target: $117.47 (+2.2% upside). Prior stop was $106.92. Stop-loss: $106.92.
Target reached (2.2% upside); Quality below floor (3.7 < 4.0).
Guardant Health, Inc. trades at a P/E of N/A (forward -159.1). TrendMatrix value score: 3.8/10. Verdict: Sell.
33 analysts cover GH with a consensus score of 4.3/5. Average price target: $131.
What does Guardant Health, Inc. do?Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests (Guardant360,...
Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests (Guardant360, Shield, Guardant Infinity) for cancer detection, therapy selection, and monitoring. It earns revenue primarily from clinical test volumes reimbursed by Medicare and commercial insurers, and from biopharmaceutical research partnerships.